Triple

Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).

Phrase: Community code for medicinal products for human use | Statement: [Directive 2001/83/EC, establishes, Community code for medicinal products for human use]

Target entity: Community code for medicinal products for human use
Context triple: [Directive 2001/83/EC, establishes, Community code for medicinal products for human use]

• A. Community register of orphan medicinal products
  The Community register of orphan medicinal products is the official European Union list of medicines designated for the diagnosis, prevention, or treatment of rare diseases, maintained under the EU’s orphan drug framework.
• B. Conditional Marketing Authorization by European Medicines Agency
  Conditional Marketing Authorization by the European Medicines Agency is a fast-track regulatory pathway that allows earlier approval of medicines, such as COVID-19 vaccines, based on less comprehensive data than normally required, provided that the benefits outweigh the risks and additional data will be supplied post-approval.
• C. World Health Organization Model List of Essential Medicines
  The World Health Organization Model List of Essential Medicines is a periodically updated catalog of the most effective, safe, and cost-efficient medicines deemed essential for meeting the priority health needs of populations worldwide.
• D. Certificates of Suitability to the monographs of the European Pharmacopoeia
  Certificates of Suitability to the monographs of the European Pharmacopoeia are official documents issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) confirming that a substance’s quality complies with the relevant European Pharmacopoeia monograph, thereby simplifying regulatory approval for medicines across Europe.
• E. Regulation (EC) No 141/2000 on orphan medicinal products
  Regulation (EC) No 141/2000 on orphan medicinal products is a key European Union law that establishes incentives and a special approval framework to encourage the development and marketing of medicines for rare diseases.
• F. None of above. chosen
• G. Unsure - the case is ambiguous/there is not enough information to decide.

Target entity: Community code for medicinal products for human use
Target entity description: The Community code for medicinal products for human use is a comprehensive European Union regulatory framework that harmonizes the authorization, supervision, and distribution of human medicines across EU member states.

• A. Community register of orphan medicinal products
  The Community register of orphan medicinal products is the official European Union list of medicines designated for the diagnosis, prevention, or treatment of rare diseases, maintained under the EU’s orphan drug framework.
• B. Conditional Marketing Authorization by European Medicines Agency
  Conditional Marketing Authorization by the European Medicines Agency is a fast-track regulatory pathway that allows earlier approval of medicines, such as COVID-19 vaccines, based on less comprehensive data than normally required, provided that the benefits outweigh the risks and additional data will be supplied post-approval.
• C. World Health Organization Model List of Essential Medicines
  The World Health Organization Model List of Essential Medicines is a periodically updated catalog of the most effective, safe, and cost-efficient medicines deemed essential for meeting the priority health needs of populations worldwide.
• D. Certificates of Suitability to the monographs of the European Pharmacopoeia
  Certificates of Suitability to the monographs of the European Pharmacopoeia are official documents issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) confirming that a substance’s quality complies with the relevant European Pharmacopoeia monograph, thereby simplifying regulatory approval for medicines across Europe.
• E. Regulation (EC) No 141/2000 on orphan medicinal products
  Regulation (EC) No 141/2000 on orphan medicinal products is a key European Union law that establishes incentives and a special approval framework to encourage the development and marketing of medicines for rare diseases.
• F. None of above. chosen